Single Cell Sequencing and Multidimensional Omics Studies in Cardiovascular and Neurological Diseases
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Blood collection
研究概览
简要总结
Research purpose Using single-cell sequencing, 3D/4D genomics and multidimensional omics technologies to reveal the complex cellular and molecular regulatory networks of cardiovascular and nervous system diseases, unique phenotypic changes of specific cell types, and different gene expression patterns, identify cell types and cell subsets associated with cardiovascular and nervous system diseases, and discover disease-related genes. To reveal new pathological mechanisms of related diseases and develop new diagnosis and treatment methods.
Research background Cardiovascular and nervous system diseases such as arrhythmias (atrial fibrillation, ventricular tachycardia, ventricular fibrillation, postoperative vascular stenosis injury, etc.), heart failure, atherosclerosis (coronary heart disease, stroke, peripheral vascular disease, carotid atherosclerosis, etc.), epilepsy, moyamoya disease, etc., are currently leading to the main diseases affecting the health and death of residents in China.
The data integration method based on single-cell sequencing, multi-omics data, and machine learning to analyze molecular level changes in cardiovascular and nervous system-related diseases can help deepen the research on the pathogenesis of cardiovascular and nervous system-related diseases and provide new ideas for the prevention and treatment of related diseases.
详细描述
- Test population Disease-specific experimental cohort of cardiovascular and neurological diseases (atrial fibrillation secondary to valvular heart disease, carotid atherosclerosis, moyamoya disease) and corresponding control cohort of normal tissue.
- Sample size calculation Through literature research and clinical diagnosis experience, reliable conclusions can be obtained with an experimental cohort of 200 or more people and a control cohort. So the experimental data were selected from a disease cohort of 200 people and a control cohort of 200 people.
- Specific research content
-
Clinical data collection Clinical data (name, age, sex, weight/height ratio (BMI), three routine procedures (blood routine, stool routine, urine routine), blood biochemistry, liver and kidney function, coagulation function, bedside electrocardiogram, 24-hour holter electrocardiogram, heart color Doppler ultrasound, carotid color Doppler ultrasound, family history, past history, medication history, treatment history, and personal history) were collected from patients who met the inclusion criteria and controls Etc.), sign a written informed consent.
-
Blood collection: Collect 5-10ml of fasting blood from the experimental population in the morning for blood routine, blood biochemistry, liver and kidney function, coagulation function and other tests.
-
Fecal collection: 3-5g feces of the experimental population without eating from 6 a.m. to 9 a.m. will be collected for stool routine and intestinal flora detection. Note: The sample must not take antibiotics and other drugs within 45 days.
-
Urine collection: Collect the first urine of the experimental group in the morning, and reserve 10-12ml of fresh midstream urine for routine urine detection.
After testing the samples collected above, the test results were put into the corresponding experimental population data. 2. Single cell sequencing
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Blood collection
时间窗: One month after the patient is clinically diagnosed with the above disease
① Collect 5-10ml blood of the subject, centrifuge, collect serum and plasma, temporarily do not test, can be immediately frozen at low temperature, the lower the temperature is better, if not repeated freezing and thawing in the middle, can be stored for one month below -20℃, can be stored for three months below -80℃. ② Citrate anticoagulant and plasma collection: Sodium citrate acts as an anticoagulant by acting on calcium ion chelation in blood samples, recommended by the National Committee for Standardization of Clinical Laboratories (NCCLS) is 3.2% or 3.8%, and the anticoagulant to blood ratio is 1: 9, mainly used in the fibrinolytic system (prothrombin time, thrombin time, activated partial thrombin time, fibrinogen). When taking blood, attention should be paid to taking enough blood to ensure the accuracy of the test results, and the blood should be gently reversed and mixed 5-8 times immediately after taking blood.
stool samples
时间窗: One month after the patient is clinically diagnosed with the above disease
① Sampling should be taken at the non-eating stage between 6am and 9am Before sampling, stool must be emptied into a clean and dry urinal or container containing filter paper. Note: Urine should not be mixed into the container. ② Use a small spoon in the sampler to collect feces. Note: In order to prevent contamination of the stool surface, gently peel the surface with a sampling spoon, and sample the inside of the stool, placing it in an average of three feces tubes. ③ After sampling, close the cover of the collector and mark the name and sampling time on the collector with a pen. Store at room temperature for 1 day, long-term storage at -80℃. Note: The sampler should not take antibiotics or other drugs for 45 days.
urine specimen
时间窗: One month after the patient is clinically diagnosed with the above disease
The first urine of the experimental group was collected in the morning and used for urine routine detection. A clean, covered, disposable volume is usually used for urine collection, and the volume of the container for urine collection is generally greater than 20mL. The container for urine collection should be labeled, including the patient's name, the specimen code and the time of urine collection. Urine should be taken within two hours as soon as possible
Single cell sequencing (control group)
时间窗: Collected during surgical treatment
During surgical treatment, at least 1mg of pathological waste tissue was collected as a sample .The corresponding single cell samples were obtained through the steps of preservation, digestion, sorting and library building. Atrial fibrillation control heart tissue sample collection: Atrial fibrillation control heart tissue was 100mg of cut waste tissue from heart transplant donor heart. Carotid atherosclerosis control sample collection: During the surgical treatment of carotid atherosclerotic plaque endarterectomy, at least 1mg of marginal tissue of discarded vascular plaque was collected as control samples. Moyamoya disease control sample collection: During cerebrovascular bypass surgery in non-moyamoya disease patients, at least 1mg of pruned waste vascular tissue was collected as a sample.
Single cell sequencing(Disease Group)
时间窗: Collected during surgical treatment
During surgical treatment, at least 1mg of pathological waste tissue was taken as a sample The corresponding single cell samples were obtained through the steps of preservation, digestion, sorting and library building. Sample collection of patients with atrial fibrillation: A small amount of useless left atrial appendage tissue 100mg was taken as a sample during surgical treatment of atrial fibrillation patients. (The tissues used in this study were either residual tissues or abandoned tissues, and both were necessary for surgical resection, so there was no additional risk for subjects.) Carotid atherosclerosis samples were collected: During the surgical treatment of carotid atherosclerotic plaque endarterectomy, at least 1mg of the central tissue of discarded vascular plaque was collected as a sample. Moyamoya disease sample collection: During cerebrovascular bypass surgery for Moyamoya disease, at least 1mg of discarded vascular tissue was collected as a sample.
次要结局
未报告次要终点
研究者
Tao Xin
Director of Neurosurgery
Qianfoshan Hospital